The primary therapeutic use of Bromhexin DAK is in providing supportive management for symptoms related to the presence of abnormal, viscous mucus in the respiratory tract.

Its classification is aligned with medicines used to assist with chest clearance. The medicine is commonly used across conditions presenting with acute or chronic respiratory issues such as bronchitis, tracheobronchitis, and symptomatic phases of Chronic Obstructive Pulmonary Disease (COPD).

Facilitating Clearance and Easing Symptom Burden

The application of this medicine is considered relevant when the consistency of the phlegm is a significant factor that interferes with successful removal. By assisting the thinning process, the medication may help manage the ineffective, non-productive cough and promote a more productive response. This generally contributes to easing the overall symptom load and supports the patient during difficult episodes by helping to relieve the sensation of chest congestion. The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and assists with maintaining functional stability against persistent, viscous secretions.

“This medicine is relevant when short-term symptomatic assistance is needed to support the patient during difficult episodes and to help relieve the sensation of chest congestion.”

---

Quick Fact: Relief for Thick Phlegm and Congestion

Property	Description
Primary Use	Symptoms of thick, sticky mucus and difficult expectoration
Symptom Relieved	Ineffective cough (to promote a more productive response) and chest heaviness
Context	Acute and chronic bronchopulmonary conditions (e.g., bronchitis)
Core Benefit	Provides support that helps ease the overall symptom burden

Regulatory References

1. Australian Therapeutic Goods Administration (TGA)

Official Population Eligibility for Bromhexin DAK

The regulatory profile for Bromhexin DAK strictly defines eligibility based on patient populations and pre-existing conditions. The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance, bromhexine hydrochloride, or any formulation excipients. Certain formulations are also contraindicated in patients with rare hereditary problems of fructose intolerance.

Use is defined by age, with Adults and children 6 years of age and over constituting the generally approved population. Use is not recommended in children under 6 years of age, and use in children younger than 2 years should only be under medical supervision.

Conditional use is required for specific clinical constraints. The medicine should be used with caution in patients with a history of peptic ulceration, and in those with severe hepatic disease or severe renal failure, due to the potential for reduced drug clearance. Furthermore, use is not recommended for breastfeeding mothers, and it is preferable to avoid use during pregnancy, especially in the first trimester.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Bromhexin DAK (Bromhexine Hydrochloride) as described in regulatory prescribing information.

Pharmacodynamic and Contraindicated Combinations

Co-administration is formally restricted or prohibited with certain medicinal products due to the risk of antagonistic effects. Combinations with antitussives (cough suppressants) or secretion-drying medications are prohibited because they counteract the mucolytic action, posing a risk of mucus accumulation in the respiratory tract. Conversely, Bromhexine co-administration is documented to result in the increased concentration of certain antibiotics (including amoxycillin, erythromycin, and oxytetracycline) in the sputum and bronchopulmonary secretions.

Pharmacokinetic and Exposure Effects

Substance	Official Interaction Pattern/Outcome
Food (Concomitant Intake)	Documented to increase Bromhexine plasma concentrations (systemic exposure).
Ampicillin, Oxytetracycline	Co-administration is officially stated to not relevantly affect the pharmacokinetics of Bromhexine.
CYP 450 2C9 or 3A4 Substrates	Relevant interactions are officially deemed unlikely, based on a lack of evidence for a change in the drug's metabolic profile.

The product's interaction profile is therefore characterized by mandatory restrictions on agents that interfere with mucociliary clearance and a documented pharmacokinetic modification linked to food intake.

Pharmacodynamic Mechanism of Bromhexin

Bromhexine functions as a secretolytic agent, targeting the production and physicochemical properties of mucus within the respiratory tract. The primary mechanism involves depolymerization of the mucopolysaccharide fibers and glycoproteins that constitute highly viscous mucus. This hydrolytic action breaks down the long molecular chains, resulting in a significant decrease in the overall viscosity and elasticity of the bronchial secretions.

Simultaneously, the molecule enhances the secretion of serous fluid from the submucosal glands in the airways. This increase in the watery component dilutes the overall mucus layer. These biochemical modifications, in turn, facilitate the ciliary beat frequency and overall mucociliary transport system. Bromhexine also accumulates selectively in the lung tissue. Furthermore, it is associated with the stimulation of pulmonary surfactant production by Type II alveolar cells, which helps reduce surface tension in the alveoli and contribute to the thinning of the mucus layer. Bromhexine is also a known inhibitor of the transmembrane protease serine 2 (TMPRSS2) enzyme.

Official Administration Guidelines for Bromhexin DAK

Bromhexin DAK, containing bromhexine hydrochloride, is intended for oral administration in formulations which include tablets, syrups, and liquid solutions. Instructions for use are non-advisory.

---

Dosage and Schedule

Instruction	Detail
Route of Administration	Oral (liquid or solid dose forms).
Standard Adult Dose	Typically 8 mg per administration, taken three times daily (t.i.d.). Regimens may temporarily allow an increase up to 16 mg per dose, reaching a daily maximum of 48 mg during the initial phase of treatment.
Administration Timing	Generally permitted to be taken with or without food, though ingestion following meals is sometimes recommended.
Duration Constraint	Use is for a short-term duration. If symptoms persist or worsen after a period of 4 to 7 days, medical evaluation is indicated.

---

Procedural and Population-Specific Rules

For liquid formulations, the supplied measuring cup or dropper must be utilized to ensure the dose is accurately administered. Pediatric dosing is age-dependent and significantly lower than the adult regimen, often administered under professional guidance for children under six years.

Specific dose modifications are utilized for patients with severe hepatic or renal impairment. Due to the risk of accumulation, the dosage is reduced or the dosing interval is lengthened under professional supervision. If a dose is missed, it must be skipped if the next dose is due soon; a double dose must never be taken.

Research evidence / Overview of Studies for Bromhexin DAK

This overview summarizes the available scientific research regarding bromhexine, the active ingredient in Bromhexin DAK. It focuses on the types of studies that have been conducted, the outcomes that researchers have measured, and where scientific uncertainties or limitations still exist.

---

Evidence for Use in Chronic Bronchitis and Chronic Obstructive Pulmonary Disease (COPD)

Research has primarily used Randomized Controlled Trials (RCTs) and summaries known as meta-analyses to evaluate this medicine in adults who have chronic conditions like bronchitis, which are characterized by an overproduction of thick, viscous mucus. These studies were applied in research contexts involving fluctuating or unstable symptoms, with researchers examining changes over defined time intervals.

In these trials, studies monitored changes in both patient-reported outcomes describing perceived discomfort and objective scientific measures. Outcomes related to physical discomfort included the ease of expectoration (coughing up mucus) and changes in overall symptom intensity or variability. For longer-term observation, studies explored patterns related to the frequency of periods of heightened symptom activity in chronic conditions.

Findings describe patterns observed in the studies related to the physical properties of sputum, indicating altered stickiness following administration. While studies report how symptoms evolved in the observed populations, changes measured during the study period related to lung function, such as FEV1, varied across different trials. The findings contribute to the broader evidence landscape for conditions where symptoms may vary in intensity.

---

Evidence for Use in Acute Bronchopulmonary Conditions

For acute respiratory tract infections, such as acute bronchitis, where there is a short-term presence of thick phlegm, research has relied on short-term clinical trials. These studies focused on outcomes describing episodic or acute changes, primarily monitoring the time needed for symptoms to resolve completely.

Evidence for this application is often derived from settings with varying symptom burdens, and research highlights changes measured during the study period. However, this evidence is limited by small sample sizes in many individual reports and a reliance on systematic reviews that may include studies published in only one regional language, which can make the certainty remain low.

---

Long-Term Studies and Follow-Up Periods

Research has explored the use of bromhexine over intermediate follow-up durations, such as periods lasting up to six months, particularly in the context of chronic bronchitis. The primary focus of these longer-term observational settings was to monitor how often periods of heightened symptom activity were observed in the populations studied.

However, the long-term effects are not fully established, and there is limited information for outcomes related to continuous use over periods significantly longer than six months. The evidence highlights what is known—and what is still uncertain—about using the medicine for maintenance support in conditions involving periods of heightened symptoms.

---

Evidence in Special Populations

Research has examined the use of the medicine in several specific groups, including older adults. In this population, studies monitor outcomes related to physiological strain or stress and patient-reported outcomes describing perceived discomfort. The results apply only to the populations studied and do not provide individual predictions for every person.

Regarding children, data for this group remain insufficient in the primary body of evidence. Studies help show what has been observed so far, but comparative evidence is lacking for children with mucus secretion issues, and subgroup findings are uncertain.

---

What Remains Uncertain in the Research Landscape

• Study Age and Methods: A number of the foundational studies are considered older, meaning they may not meet the stringent standards of contemporary trial methodology, such as robust blinding or patient selection.
• Inconsistency in Measurement: Findings were mixed concerning objective measures, such as lung function ( FEV1), with some trials reporting changes that were not consistently observed.
• Study Limitations: Follow-up durations were limited in most trials, and in many of the studies that exist, sample sizes were modest. This means the research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. R05CB02 - Bromhexine - Anatomical Therapeutic Chemical (ATC) Classification Index
2. Australian Product Information – Bisolvon Chesty (Bromhexine Hydrochloride)

Common questions about Bromhexin DAK (FAQ)

Q: Is Bromhexin DAK available over the counter in most countries?

A: According to official product classification in many regions, this medicine is categorized as non-prescription or a Pharmacy-only medicine. This means that in these areas, it can often be purchased without needing a doctor’s prescription. Availability and requirements can vary depending on the local regulatory body.

Q: Can elderly patients generally use Bromhexin DAK safely?

A: Official information indicates that the drug has been included in research involving older adults. However, if a patient has severe kidney or liver impairment, professional supervision may be needed for dosage adjustments. This caution is due to the potential for the body’s ability to clear the medicine to be reduced in such cases.

Q: Is Bromhexin DAK generally considered safe for short-term use?

A: Regulatory documents state that the medicine is authorized for and recommended strictly as a short-term use medicine. If your symptoms persist or worsen after approximately four to seven days of use, official guidance recommends that a medical professional be consulted.

Q: Are there any specific organs that process Bromhexin DAK?

A: Official product information indicates that the active ingredient is primarily processed (metabolized) by the liver. The majority of the medicine and its related substances are then eliminated from the body via the kidneys, typically through urine excretion.

Q: What should be done if a potential serious side effect is suspected?

A: In the rare event that a serious reaction is suspected, such as a progressive or worsening skin rash, or signs of a severe allergic reaction like difficulty breathing or swelling, official guidance indicates that the medicine should be discontinued immediately. In such situations, seeking emergency medical attention is advised.

Q: Is Bromhexin DAK intended for a cold or for deeper respiratory infections?

A: The medicine is indicated for secretolytic therapy in bronchopulmonary diseases that involve abnormal, thick mucus secretion. This scope includes conditions such as acute bronchitis. The drug's purpose is to help loosen thick phlegm.

Q: How quickly can a person expect Bromhexin DAK to start working?

A: According to official product information, the active ingredient is described as being rapidly absorbed from the gastrointestinal tract after being taken by mouth. This refers to how quickly the substance enters the bloodstream.

Q: Can Bromhexin DAK be used alongside common pain relievers like paracetamol?

A: Official regulatory labeling does not list specific contraindications or significant known interactions with common pain relievers. The general interaction section states there are no known significant interactions with other medicines.

Q: How long does the effect of Bromhexin DAK typically last in the body?

A: Regulatory documents on pharmacokinetics describe the terminal elimination half-life of the active ingredient as being up to approximately 12 hours. The half-life refers to the time it takes for half of the drug to be eliminated from the body.

Q: Does Bromhexin DAK contain any ingredients known to cause drowsiness?

A: While the medicine is not typically classified as a sedative, dizziness (vertigo) is listed among the rare side effects in official documentation. Dizziness is a central nervous system effect that may potentially affect your alertness.

Q: Are there any known interactions between Bromhexin DAK and supplements like Vitamin C?

A: Official regulatory labeling does not specifically mention interactions with common vitamins or supplements like Vitamin C. The interaction profile states that there are no known significant interactions with other medicines.

Q: Can Bromhexin DAK be taken by individuals who are lactose intolerant?

A: Certain dosage forms, specifically tablets, may contain excipients (inactive ingredients) such as lactose. Official guidelines indicate that these formulations are generally unsuitable for individuals with known galactose intolerance.

Q: Is Bromhexin DAK known to interact with blood pressure medications?

A: The official interaction profile, based on regulatory labeling, does not list specific blood pressure medications as known interacting substances with Bromhexin DAK.

Q: Can Bromhexin DAK affect the results of any common medical tests?

A: Official adverse reaction reports indicate that a transient rise in serum aminotransferase values has been reported occasionally. This value is a laboratory measure of liver enzyme levels that may change during use.

Q: Are there official warnings about combining Bromhexin DAK with certain types of alcohol?

A: Safety advice derived from official documentation suggests caution when consuming alcohol while using this medicine. This is because alcohol consumption may potentially increase the risk of central nervous system effects, such as dizziness.

Q: Why do people sometimes recommend drinking more water when using Bromhexin DAK?

A: General health advice often suggests drinking plenty of fluids when taking this type of medicine. This is believed to help enhance the medicine's effect of loosening the mucus in the airways.

Q: Is Bromhexin DAK considered a habit-forming medicine?

A: According to regulatory safety information, the active ingredient in this medicine is not known to be habit-forming or associated with dependencies.

The official storage and disposal requirements for bromhexine hydrochloride syrup (e.g., Bromhexin DAK) are explicitly defined in regulatory documentation.

Storage Conditions

Requirement	Classification
Maximum Temperature	Do not store above 30 C
Light Protection	Keep inside the outer carton to protect from light
Container Rule	Store in the original container
Child Safety	Must be kept out of the reach of children

Stability and Disposal

The unopened product has a shelf life of three years. After the bottle is opened, the product must be used within 12 months, according to labeling for some oral solutions. Regarding disposal, official documents state there are no special requirements for discarding unused or expired product, and disposal should follow local waste regulations.